Amphiregulin in Fibrotic Diseases and Cancer

Amphiregulin (AREG) is identified as a significant mediator in fibrotic diseases and cancer, acting through dual signaling pathways that involve both EGFR-dependent and -independent mechanisms. Elevated AREG expression is linked to increased disease severity in organs like the lungs, kidneys, liver, and heart. Targeting AREG has shown potential in providing antifibrotic and anticancer benefits, with therapies like SAMiRNA-AREG demonstrating specificity and safety in preclinical and early clinical trials. This suggests that AREG could be a promising target for precision medicine, potentially improving outcomes by personalizing treatment based on AREG expression levels.